Drug Trial Radar · NCT01674036
Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men
Last checked: Nov 19, 2026Latest source record: Mar 19, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
Aug 2012
Primary completion
Jan 2013
Study completion Jan 2013
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 28, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objectives of this study are to assess the tolerability, safety and pharmacokinetic parameters of Genz-682452 in healthy adult males, in two parts. Part 1 (GZFD00111TDU12766): double-blind, randomized, placebo-controlled, sequential ascending single dose study; Part 2 (GZFD00211FED12767): open-label, randomized, 2-sequence, 2-period, 2-treatment crossover study with a minimum wash-out period; to obtain preliminary information on the pharmacokinetics, tolerability and safety of Genz-682452 after single oral doses in fed and fasted conditions. Subjects are not allowed to participate in more than 1 part of the study.
Conditions
- Healthy Volunteer
Interventions
Genz-682452Drug
Capsules for oral administration.
PlaceboDrug
Placebo to Genz-682452
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events in Part 1Time frame: Up to 4 weeks
- Number of participants with adverse events in Part 2Time frame: Up to 5 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.